237 related articles for article (PubMed ID: 32482320)
21. [Drug clinics. How I treat cutaneous melanoma].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
[TBL] [Abstract][Full Text] [Related]
22. How does interferon work? Does it even matter?
Sondak VK
Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
[No Abstract] [Full Text] [Related]
23. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
24. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
25. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
26. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
28. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
29. Subungual Melanoma In Situ Treated With Imiquimod 5% Cream After Conservative Surgery Recurrence.
Ocampo-Garza J; Gioia Di Chiacchio N; Haneke E; le Voci F; Paschoal FM
J Drugs Dermatol; 2017 Mar; 16(3):268-270. PubMed ID: 28301623
[TBL] [Abstract][Full Text] [Related]
30. [Adjuvant systemic treatment of melanoma].
Kähler KC; Egberts F; Hauschild A; Mohr P
Hautarzt; 2011 Jun; 62(6):414, 416-22. PubMed ID: 21656113
[TBL] [Abstract][Full Text] [Related]
31. [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].
Hauschild A; Volkenandt M; Garbe C
Dtsch Med Wochenschr; 2000 Oct; 125(42):1272-8. PubMed ID: 11098240
[No Abstract] [Full Text] [Related]
32. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
33. [Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
Marcoval J; Ferreres JR; Penín RM; Piulats JM; Caminal JM; Fabra A
Actas Dermosifiliogr; 2011 Dec; 102(10):791-6. PubMed ID: 21658662
[TBL] [Abstract][Full Text] [Related]
34. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy of malignant melanoma.
Nathanson L; Jilani S
Cancer Treat Res; 1993; 65():335-54. PubMed ID: 8104027
[No Abstract] [Full Text] [Related]
37. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.
Meyskens FL; Kopecky KJ; Taylor CW; Noyes RD; Tuthill RJ; Hersh EM; Feun LG; Doroshow JH; Flaherty LE; Sondak VK
J Natl Cancer Inst; 1995 Nov; 87(22):1710-3. PubMed ID: 7473820
[No Abstract] [Full Text] [Related]
38. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
39. Therapy for metastatic melanoma: the past, present, and future.
Finn L; Markovic SN; Joseph RW
BMC Med; 2012 Mar; 10():23. PubMed ID: 22385436
[TBL] [Abstract][Full Text] [Related]
40. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
